Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anbio BiotechnologyNNNN -1.15%24 ROC (Joel Greenblatt) % is 29.65% as of Dec. 2025, which is 37% below its 10-year median of 46.70. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 87.95% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Anbio Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 29.65%.
The historical rank and industry rank for Anbio Biotechnology's ROC (Joel Greenblatt) % or its related term are showing as below:
NNNN'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 39.46 Med: 46.7 Max: 258.82
Current: 46.24
During the past 5 years, Anbio Biotechnology's highest ROC (Joel Greenblatt) % was 258.82%. The lowest was 39.46%. And the median was 46.70%.
NNNN's ROC (Joel Greenblatt) % is ranked better than 87.95% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs NNNN: 46.24
Anbio Biotechnology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Anbio Biotechnology ROC (Joel Greenblatt) % Related Terms
Anbio Biotechnology ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 29.65% mean?
Anbio Biotechnology (NNNN) has a ROC (Joel Greenblatt) % of 29.65% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Anbio Biotechnology and its competitors. This is 37% below median its historical median of 46.70. Over the past decade, Anbio Biotechnology's ROC (Joel Greenblatt) % has ranged from 39.46 to 258.82. According to the industry distribution chart, Anbio Biotechnology ranks #101 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 12.1%.
Is Anbio Biotechnology's ROC (Joel Greenblatt) % too high?
Anbio Biotechnology's current ROC (Joel Greenblatt) % of 29.65% is 37% below median its 10-year median of 46.70. Over the past 10 years, this metric has ranged from a low of 39.46 to a high of 258.82. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Anbio Biotechnology's value of 29.65% is 615.3% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #101 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's ROC (Joel Greenblatt) % compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #101 out of 838 companies for ROC (Joel Greenblatt) %. This places Anbio Biotechnology in the top 12% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.15. Anbio Biotechnology's value of 29.65% is 615.3% above this benchmark. Historically, Anbio Biotechnology's own ROC (Joel Greenblatt) % has ranged from 39.46 to 258.82 over the past decade. While the company's 10-year median is 46.70 vs. the industry median of 4.15, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current ROC (Joel Greenblatt) % of 29.65% is 615.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current ROC (Joel Greenblatt) % is 29.65%, which is 37% below median its own 10-year median of 46.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current ROC (Joel Greenblatt) % of 29.65%. The current ROC (Joel Greenblatt) % is 29.65%, which is 37% below median its 10-year median of 46.70 and 615.3% above the Medical Devices & Instruments industry median of 4.15. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current ROC (Joel Greenblatt) % is 29.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
